ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma

New England Journal of Medicine

Volumn 366, Issue 5, 2012, Pages 399-408

  Meyer, Ralph M ^a   Gospodarowicz, Mary K ^b   Connors, Joseph M ^c   Pearcey, Robert G ^d   Wells, Woodrow A ^b   Winter, Jane N ^h   Horning, Sandra J ⁱ   Dar, A Rashid ^e   Shustik, Chaim ^f   Stewart, Douglas A ^g   Crump, Michael ^b   Djurfeldt, Marina S ^a   Chen, Bingshu E ^a   Shepherd, Lois E ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

^e UNIVERSITY OF WESTERN ONTARIO   (Canada)

^f MCGILL UNIVERSITY   (Canada)

^g UNIVERSITY OF CALGARY   (Canada)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; VINBLASTINE;

ARTICLE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; DRUG FATALITY; EVENT FREE SURVIVAL; FOLLOW UP; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SUBTOTAL NODAL RADIATION THERAPY;

EID: 84863011979     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1111961     Document Type: Article

References (31)

1. Carde P, Burgers JM, Henry-Amar M, et al. Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors. J Clin Oncol 1988;6:239-52. (Pubitemid 18068598)
2. Carde P, Hagenbeek A, Hayat M, et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1993;11:2258-72. (Pubitemid 23332265)
3. Dores GM, Metayer C, Curtis RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol 2002;20:3484-94.
4. Meyer RM, Ambinder RF, Stroobants S. Hodgkin's lymphoma: evolving concepts with implications for practice. Hematology Am Soc Hematol Educ Program 2004;1:184-202.
5. Ng AK, LaCasce A, Travis LB. Long-term complications of lymphoma and its treatment. J Clin Oncol 2011;29:1885-92.
6. Swerdlow AJ, Higgins CD, Smith P, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 2007;99:206-14.
7. Press OW, LeBlanc M, Lichter AS, et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol 2001;19:4238-44. (Pubitemid 33081641)
8. Hagenbeek A, Eghbali H, Ferme C, et al. Three cycles of MOPP/ABV hybrid and involved-field irradiation is more effective than subtotal nodal irradiation in favorable supra-diaphragmatic clinical stages I-II Hodgkin's disease: preliminary results of the EORTC-GELA H8-F randomized trial in 543 patients. Blood 2000;96:Suppl: 575a. abstract.
9. Engert A, Franklin J, Eich HT, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 2007;25:3495-502. (Pubitemid 47310889)
10. Fermé C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 2007;357:1916-27. (Pubitemid 350074687)
11. Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010;363:640-52.
12. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478-84.
13. Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003;21:607-14. (Pubitemid 46621893)
14. Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:4634-42. (Pubitemid 46237440)
15. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7:1630-6. [Erratum, J Clin Oncol 1990;8:1602.] (Pubitemid 19272832)
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
17. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-48.
18. Meyer R, Gospodarowicz M, Connors J, et al. A randomized phase III comparison of single-modality ABVD with a strategy that includes radiation therapy in patients with early-stage Hodgkin's disease: the HD-6 Trial of the National Cancer Institute of Canada Clinical Trials Group (Eastern Cooperative Group Oncology Group Trial JHD06). Blood 2003;102:Suppl:26a. abstract.
19. Diehl V. Hodgkin's disease - from pathology specimen to cure. N Engl J Med 2007;357:1968-71. (Pubitemid 350074695)
20. Canellos GP. Chemotherapy alone for early Hodgkin's lymphoma: an emerging option. J Clin Oncol 2005;23:4574-6. (Pubitemid 46224056)
21. Longo DL. From the guest editor: Hodgkin's lymphoma: an overview. Cancer J 2009; 15:114-6.
22. Straus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 2004;104:3483-9. (Pubitemid 39564416)
23. Laskar S, Gupta T, Vimal S, et al. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol 2004;22:62-8. (Pubitemid 41095115)
24. Nachman JB, Sposto R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 2002;20:3765-71.
25. Herbst C, Rehan F, Skoetz N, et al. Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma. Cochrane Database Syst Rev 2011;2:CD007110.
26. Hoppe RT, Advani RH, Ai WZ, et al. Hodgkin lymphoma. J Natl Compr Canc Netw 2011;9:1020-58.
27. Engert A, Eichenauer DA, Dreyling M. Hodgkin's lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21:Suppl 5:v168-v171.
28. Radford J. Limited-stage disease: optimal use of chemotherapy and radiation treatment. Hematology Am Soc Hematol Educ Program 2008;1:321-5.
29. Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol 2009;27:1906-14.
30. Gallamini A, O'Doherty M. Report of satellite workshop on interim-PET in Hodgkin lymphoma: 8th International Symposium on Hodgkin Lymphoma, Cologne, October 2010. Leuk Lymphoma 2011;52:583-6.
31. Tomlinson G, Detsky AS. Composite end points in randomized trials: there is no free lunch. JAMA 2010;303:267-8.